Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A second buffer dose ranging study of LTX-03

Trial Profile

A second buffer dose ranging study of LTX-03

Phase of Trial: Phase I

Latest Information Update: 13 Oct 2017

At a glance

  • Drugs Hydrocodone/paracetamol (Primary)
  • Indications Pain
  • Focus Adverse reactions
  • Most Recent Events

    • 13 Oct 2017 New trial record
    • 09 Oct 2017 This study is expected to commence in the 4Q 2017 with topline results in the 1Q 2018, as reported in an Acura Pharmaceuticals. The Company expects to complete this next study in the first quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top